BRPI0919426A2 - métodos melhorado de exposição de rna - Google Patents

métodos melhorado de exposição de rna

Info

Publication number
BRPI0919426A2
BRPI0919426A2 BRPI0919426A BRPI0919426A BRPI0919426A2 BR PI0919426 A2 BRPI0919426 A2 BR PI0919426A2 BR PI0919426 A BRPI0919426 A BR PI0919426A BR PI0919426 A BRPI0919426 A BR PI0919426A BR PI0919426 A2 BRPI0919426 A2 BR PI0919426A2
Authority
BR
Brazil
Prior art keywords
exposure methods
enhanced rna
rna exposure
enhanced
methods
Prior art date
Application number
BRPI0919426A
Other languages
English (en)
Inventor
Chungming Hsieh
John E Memmott
Yuliya A Kutskovva
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0919426A2 publication Critical patent/BRPI0919426A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0919426A 2008-09-30 2009-09-30 métodos melhorado de exposição de rna BRPI0919426A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10147108P 2008-09-30 2008-09-30
PCT/US2009/059057 WO2010039850A1 (en) 2008-09-30 2009-09-30 Improved method of rna display

Publications (1)

Publication Number Publication Date
BRPI0919426A2 true BRPI0919426A2 (pt) 2015-12-15

Family

ID=42073857

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919426A BRPI0919426A2 (pt) 2008-09-30 2009-09-30 métodos melhorado de exposição de rna

Country Status (16)

Country Link
US (1) US8916504B2 (pt)
EP (1) EP2342562B1 (pt)
JP (1) JP5968624B2 (pt)
KR (1) KR20110076906A (pt)
CN (1) CN102227638B (pt)
AU (1) AU2009298499A1 (pt)
BR (1) BRPI0919426A2 (pt)
CA (1) CA2737035A1 (pt)
ES (1) ES2434850T3 (pt)
IL (1) IL211551A (pt)
MX (1) MX2011003381A (pt)
NZ (1) NZ591544A (pt)
RU (1) RU2011117210A (pt)
TW (1) TW201024731A (pt)
WO (1) WO2010039850A1 (pt)
ZA (1) ZA201102120B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
BRPI1012195A2 (pt) * 2009-05-01 2018-04-24 Abbott Laboratories imunoglobulinas de domínio variável duplo e usos das mesmas
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR078651A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PH12012501070A1 (en) * 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en) * 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3798236B1 (en) 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP2975121A4 (en) * 2013-03-13 2016-07-20 Univ Tokyo NUCLEIC LEFT
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US10370651B2 (en) * 2013-06-28 2019-08-06 X-Body, Inc. Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
JP6814634B2 (ja) 2014-02-05 2021-01-20 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3549606A1 (en) * 2015-05-28 2019-10-09 Bio-rad Laboratories, Inc. Affinity ligands and methods relating thereto
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
CN111511768B (zh) * 2017-11-20 2024-03-26 南特生物科学公司 mRNA展示抗体文库和方法
CN113710801B (zh) * 2019-02-22 2024-07-09 爱普思隆分子进化工程株式会社 一种使用cDNA展示的新型免疫PCR方法
CN114585736B (zh) * 2020-10-27 2023-05-02 北京寻因生物科技有限公司 一种嘌呤霉素连接子及其在体外核酸展示肽合成中的应用
WO2022104001A1 (en) 2020-11-13 2022-05-19 Bristol-Myers Squibb Company Expanded protein libraries and uses thereof
WO2026025103A1 (en) * 2024-07-26 2026-01-29 The Children's Medical Center Corporation Methods of modulating growth factor activity
WO2026063389A1 (ja) * 2024-09-17 2026-03-26 Jnc株式会社 多孔質粒子ならびにそれを含む吸着剤およびクロマトグラフィー担体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310652A (en) * 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK0985032T4 (da) * 1997-05-28 2009-08-31 Crescendo Biolog Ltd Ribosom-komplekser som selektionspartikler til in vitro fremvisning og evolution af proteiner
US6927025B1 (en) * 1997-09-03 2005-08-09 Biovation Limited Methods for protein screening
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
SI1187632T1 (sl) * 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
US6830902B1 (en) * 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
CA2377468C (en) * 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
US7264932B2 (en) * 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
WO2001075097A2 (en) * 2000-03-31 2001-10-11 Cambridge Antibody Technology Limited Improvements to ribosome display
JP4963142B2 (ja) * 2000-12-14 2012-06-27 学校法人慶應義塾 遺伝子型と表現型の対応付け分子とその構成要素、および対応付け分子の製造方法と利用方法
ES2615362T3 (es) * 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
EP1554392A4 (en) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF NEW NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH WIDE CROSS-REACTIVITY USING SEQUENTIAL ANTIGEN PANNING OF PHAG DISPLAY LIBRARIES
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2504443A1 (en) * 2002-10-30 2004-05-13 Pointilliste, Inc. Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
BRPI0417302A (pt) * 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
US8822191B2 (en) * 2004-02-04 2014-09-02 Novo Nordisk A/S Methods of refolding mammalian glycosyltransferases
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JP2006141348A (ja) * 2004-11-24 2006-06-08 Zoegene Corp 標的物質と相互作用するドメインポリペプチドの選抜取得方法および構造モチーフ配列の同定方法並びに分子設計方法
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
US20070218478A1 (en) * 2005-12-16 2007-09-20 Affymetrix, Inc. Methods for fragmentation and analysis of nucleic acid
JP2007191477A (ja) * 2005-12-22 2007-08-02 Cellfree Sciences Co Ltd 風疹ウイルスタンパク質の製造方法
EA015992B1 (ru) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
US7749957B2 (en) * 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
WO2007136835A2 (en) * 2006-05-19 2007-11-29 Codon Devices, Inc Methods and cells for creating functional diversity and uses thereof

Also Published As

Publication number Publication date
CA2737035A1 (en) 2010-04-08
EP2342562A1 (en) 2011-07-13
MX2011003381A (es) 2011-04-21
US20100105569A1 (en) 2010-04-29
EP2342562B1 (en) 2013-09-18
KR20110076906A (ko) 2011-07-06
ES2434850T3 (es) 2013-12-17
JP5968624B2 (ja) 2016-08-10
NZ591544A (en) 2013-01-25
US8916504B2 (en) 2014-12-23
AU2009298499A1 (en) 2010-04-08
IL211551A (en) 2014-06-30
EP2342562A4 (en) 2012-03-21
ZA201102120B (en) 2011-12-28
TW201024731A (en) 2010-07-01
WO2010039850A1 (en) 2010-04-08
CN102227638A (zh) 2011-10-26
RU2011117210A (ru) 2012-11-10
JP2012504415A (ja) 2012-02-23
HK1159250A1 (en) 2012-07-27
CN102227638B (zh) 2015-05-20
IL211551A0 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
BRPI0919116A2 (pt) método
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
EP3988147C0 (en) INSERT SET
DE602009000234D1 (de) msignals
BRPI0911841A2 (pt) processos de modelagem
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2313489T3 (da) Fremstillingsmetode
DK2342454T3 (da) Vindkraftanlæg
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
BRPI0911625A2 (pt) Métodos
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
BRPI0915562A2 (pt) tamis melhorado
BRPI0915442A2 (pt) tamis melhorado
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0809678A2 (pt) Métodos
BRPI0810416A2 (pt) Método de hidroformação
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
BRPI0916597A2 (pt) Método
DE602009000488D1 (de) Obstvereinzelvorrichtung

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.